PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, primary myelofibrosis, polycythemia vera, and essential thrombocythemia. The company licensed to develop Oraxol for the treatment of breast, gastric, gastro-esophageal, and esophageal cancer; and KX01 for the treatment of psoriasis. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.